SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-074706
Filing Date
2024-03-22
Accepted
2024-03-22 09:26:31
Documents
13
Period of Report
2024-03-19
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d17601d8k.htm   iXBRL 8-K 28310
  Complete submission text file 0001193125-24-074706.txt   151055

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ntla-20240319.xsd EX-101.SCH 2847
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20240319_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20240319_pre.xml EX-101.PRE 11259
16 EXTRACTED XBRL INSTANCE DOCUMENT d17601d8k_htm.xml XML 3630
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 24773392
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)